LabCentrixSM Becomes Reseller of BioRails

LabCentrixSM Becomes Reseller of BioRails

Leading LIMS consultancy expands its informatics offerings with a productivity tool that helps labs manage service requests more efficiently. The BioRails™ software provides additional workflow and scheduleing capabilities that will operate in tandem with LIMS software packages such as the Thermo Scientific Nautilus software.

Hudson, Mass. (PRWEB) March 3, 2009 -- LabCentrixSM LLC, a premier provider of Laboratory Information Management Systems (LIMS) consulting services (http://www.labcentrix.com/consulting.htm)and lab technology solutions, has entered into a reseller agreement with The Edge Software Consultancy Ltd to distribute BioRails™ in North America and Brazil. The BioRails software is a productivity tool that enables laboratories to manage service requests and resources more efficiently.

LabCentrix specializes in helping laboratories of all sizes gain operational efficiencies through the effective use of technology. With the BioRails software, LabCentrix will address the challenge labs face in managing service requests, prioritizing workloads and assessing the best use of available resources. BioRails provides additional workflow and scheduling capabilities that will operate in tandem with LIMS software solutions.

"LIMS software packages do a great job of automating sample management once a sample is in the lab, BioRails automates the process of managing requests as they are submitted to a lab and the resource decisions that occur from there," said Mike Lujan, CEO and founder of LabCentrix. "We're very impressed with the sophistication of the BioRails software (http://www.edgesoftwareconsultancy.com/Preclinical_Study_management.htm)and believe it solves a widespread need, particularly in large multi-lab operations with high service requests volumes."

"We are very excited about our new partnership with LabCentrix and the strong market opportunity they recognize for BioRails," said Andrew Lemon, managing director of The Edge Software Consultancy. "BioRails is a natural extension of LabCentrix' services and offers a valuable new technology solution for both its current and new customers."

LabCentrix' principals have more than 25 years combined experience in implementing leading LIMS systems such as the Thermo Scientific Nautilus LIMS software (http://www.thermo.com).

About LabCentrix

LabCentrixSM LLC is a premier provider of Laboratory Information Management Systems (LIMS) consulting services and technology solutions for a range of industries, including pharmaceutical, biotech, healthcare, process, forensics, environmental, petroleum and others. LabCentrix customers, who cover the spectrum from multinational giants to small- and mid-sized organizations, receive measurable value from the company's unique approach to maximizing a lab's informatics investments. Building on a profound knowledge of technology, laboratory processes and preferred business practices, LabCentrix collaborates closely with each customer's teams to efficiently deliver individualized solutions that specifically address their needs. LabCentrix also offers technology solutions that extend the value of LIMS software packages including its SmartManager™ for Nautilus and Affinity for Affymetrix. For more information about LabCentrix and its consulting services, value-add technology solutions and personalized support offerings, visit www.labcentrix.com or contact us at +1 888 708-8781.

About The Edge Software Consultancy

The Edge Software Consultancy is a multidisciplinary consulting organization offering solutions across all aspects of drug discovery information management. Its consultants are seasoned professionals offering the benefit of extensive real-world experience in drug discovery. The Edge offers a range of services including business process analysis, project management, requirements preparation, technical specification, implementation and testing. The consultancy is also known for its independent integration services and guidance on software selection and interoperability. Its unique approach identifies bottlenecks, concentrating on the goals of your scientists; targeting recovery of a day a week of your scientists' time and to reduce the frustration that accompanies so many software users experience. For more information visit www.edgesoftwareconsultancy.com (http://www.edgesoftwareconsultancy.com/index.htm).

###

Contact Information Mike Lujan

LabCentrix LLC

http://www.labcentrix.com

(978) 562-6973

New ScriptStroyer Pharmacy Shredder Introduced at MyBinding.com

New ScriptStroyer Pharmacy Shredder Introduced at MyBinding.com

MyBinding.com announced today the introduction of the new Martin Yale UC5500 ScriptStroyer Pharmacy Shredder. This new shredder is designed specifically for pharmacies and pharmacists who need to shred pill bottles, perscription containers and confidential printed labels. The UC5500 shredder offers new technology that allows for shredding of both wet and dry containers and prevents the buildup of adhesive residue on the shredding head.

Hillsboro, OR (PRWEB) March 2, 2009 -- MyBinding.com (http://www.mybinding.com) announced today the introduction of the new Martin Yale UC5500 ScriptStroyer Pharmacy Shredder (http://www.mybinding.com/.sc/ms/dd/ee/52260/Martin-Yale-UC5500-ScriptStroyer-Pharmacy-Pill-Bottle-Shredder). This new and innovative shredding device was designed by Martin Yale Industries to address identity theft and HIPAA compliance concerns facing pharmacies around the world. The UC5500 ScriptStroyer shredder is designed to shred prescription bottles and caps as well as other plastic bottles up to 3-1/2" in diameter.

The release of the ScriptStroyer Shredder (http://www.mybinding.com/.sc/ms/cat/Shredders) comes in response to a rising tide of concern over the handling of confidential patient information by pharmacies and pharmacists. Nearly every prescription bottle produced by a pharmacy contains sensitive information protected by the Health Insurance Portability and Accountability Act (HIPAA). HIPAA requires that organizations such as pharmacies put in safeguards to protect personal health information from being disclosed improperly or unnecessarily. Using a pharmacy shredder such as the UC5500, pharmacists can now ensure their own compliance with patient privacy laws.

In addition to handling empty prescription bottles, the UC5500 is also ideal for handling other confidential information used by pharmacists. Many pharmacies produce hundreds or thousands of excess prescription labels per day. These excess labels along with patient instructions often contain the same information included on a pill bottle. In order to protect patient confidentiality and prevent lapses in compliance, these excess labels and documents also need to be destroyed. The Martin Yale ScriptStroyer Shredder helps to ensure that the destruction of this type of information is convenient and secure.

The ScriptStroyer shredder is designed to slide inconspicuously under a pharmacist's counter so that empty bottles and unused prescription labels can be immediately destroyed. The shredder uses a new technology that bathes the shredding head in oil allowing it to shred both wet and dry prescription bottles without concern that cough syrups and other substances will cause damage to the unit. In fact, the unit can easily handle adhesive labels which are problematic for many other shredders. It has a compartment for shredding prescription bottles and also has a slot designed to shred up to 10 sheets of paper or label stock. Both paper and plastic are shredded into particles that are 5/32" x 1-1/2" in size.

MyBinding.com was selected by Martin Yale Industries as one of only a handful of dealers authorized to distribute the UC5500 ScriptStroyer shredder. MyBinding carries the full line of Martin Yale (http://www.mybinding.com/.sc/ms/ch/Martin-Yale-Shredders-and-Paper-Handling-Equipment.html) and Intimus Shredders (http://www.mybinding.com/.sc/ms/ch/Intimus-Paper-Handling-Equipment-And-Paper-Shredders.html) and paper handling equipment. In fact they are among a select group of dealers that is authorized to sell the complete line of Martin Yale Intimus Industrial Paper Shredders.

###

Contact Information Jeff McRitchie

MyBinding.com

http://www.mybinding.com

1-800-944-4573

AnaptysBio Selects Gable PR of San Diego for National Communications Program During Key Phase in Growth

AnaptysBio Selects Gable PR of San Diego for National Communications Program During Key Phase in Growth

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company seeking expanded outreach to the biotech and pharma industries, has selected Gable PR of San Diego to provide national public relations and investor communications programs as a key part of the company's strategic growth plan for 2009 and beyond.

San Diego, Calif. (PRWEB) March 2, 2009 -- AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has selected Gable PR to provide public relations and investor communications programs as a key part of the company's strategic growth plan for 2009 and beyond. Gable PR is a growing public relations firm based in San Diego and known for its sophisticated and successful approach to managing complex programs for national biotech companies and organizations.

"Gable PR will play a vital role in helping us communicate with key audiences about the advantages of our platform for antibody discovery," said Tom Smart, AnaptysBio chairman and CEO. "We selected Gable PR because of their past successes helping biotech companies with complex messages reach out to broader industry audiences. We anticipate achieving several important milestones in 2009 in validating our platform and need an agency partner that can take charge of getting out the word in a very targeted way to potential partners and investors."

AnaptysBio has developed a platform for generating therapeutic antibodies that is unique in the field. The platform mimics the body's natural evolution and selection processes for creating potent antibodies to fight disease. As a result, AnaptysBio believes the antibodies generated by its platform will result in therapies that are highly effective and better tolerated by the human body. Competing platforms often require scientists make artificial changes to antibodies, resulting in lower likelihood that they will be well tolerated.

"In checking out competing companies, we were impressed with the clear advantages AnaptsyBio demonstrated with the quality of its team, technology and culture," said Tom Gable, CEO of Gable PR. "They have a clear vision to 2010 and beyond and we're pleased to have been selected to help them reach key partners and potential investors with their story and data."

AnaptysBio's public relations program will be managed by Erin Koch, Gable PR director. The agency team includes professionals with significant investor relations, media relations, and media training experience.

About AnaptysBio:

Founded in 2005, AnaptysBio, Inc is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform™ utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection - a process that has been referred to as "naturalizing" antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. The company has established broad intellectual property around the use of SHM for therapeutic antibody applications, and is currently building a pipeline of novel therapeutic antibody product candidates. For more information, visit www.anaptysbio.com.

About Gable PR:

Gable PR, based in San Diego, delivers highly effective public relations and marketing communications programs for clients in a broad range of industries. Its tradition of success goes back 30 years with Tom Gable, APR, PRSA Fellow and a nationally recognized authority on the strategic use of public relations for positioning, reputation management and delivering meaningful results. Clients have included private and public companies, organizations, institutions and government agencies at every stage in their life cycles, from start-up to a Fortune 100 company (Pfizer). Agency programs have earned the highest honors in the PR profession and helped clients of all sizes and needs succeed. For more information: www.gablepr.com.

###

Contact Information TOM GABLE

Gable PR

http://www.gablepr.com

619-284-1714

FDA Meeting on Opioid REMS Highlights the Need for Comprehensive, Integrated Risk Management

FDA Meeting on Opioid REMS Highlights the Need for Comprehensive, Integrated Risk Management

Inflexxion is uniquely positioned to assist companies with risk evaluation and mitigation strategy plans

Newton, MA (PRWEB) March 2, 2009 -- On Tuesday, March 3rd, the FDA will meet with manufacturers of extended-release (ER) opioid medications for what's expected to be the beginning of a process to develop a new Risk Evaluation and Mitigation Strategy (REMS) program. According to the Agency, strategies for minimizing the risks of opioid medications -- which have included FDA-required risk minimization and action plans, or RiskMAPs -- need to be strengthened.

"Despite [the efforts of the FDA, drug manufacturers, and other stakeholders, the rates of misuse and abuse, and of accidental overdose of opioids, have risen over the past decade," states the Agency in a media release announcing the meeting. Crafting a new REMS program, the Agency says, will entail "discussions with other federal agencies and non-government institutions, including patient and consumer advocates, representatives of the pain and addiction treatment communities, other health care professionals, and other interested parties."

Inflexxion, a company that is deeply engaged with the pain and addiction treatment communities, is uniquely prepared to assist manufacturers, federal agencies, and other stakeholders with creating a comprehensive REMS. In 2001, the company's pharmaceutical risk-management division launched development of the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) with support from the National Institutes of Health (NIH). Now a nationally recognized public health-oriented substance risk management solution, NAVIPPRO integrates the four key components of an effective REMS: national, "real-time," product-specific surveillance; signal detection; signal verification; and empirically validated prevention and intervention programs.

"One of the key elements distinguishing REMS from RiskMAPs is the requirement for ongoing evaluation of the efficacy of a program, both by the FDA and the sponsor of the drug, so adjustments can be made to ensure that risk-mitigation goals are being met," says Kevin Zacharoff, M.D., Director of Medical Affairs at Inflexxion. "NAVIPPRO is designed to assist with this type of long-term, continuous evaluation."

In a recent study of NAVIPPRO data published in Pharmacoepidemiology and Drug Safety (December 2008, Volume 17, Issue 12), the authors evaluated the surveillance component of the program. Analyzing NAVIPPRO's proprietary, "real-time" data stream, de-identified client assessment data continuously collected from the ASI-MV® Connect network of substance abuse clinics across the U.S., they examined the representativeness, geographic coverage, and timeliness of report of the data. They found that the data allow for the characterization of product-specific and geo-spatial differences for drug abuse, and can serve as a tool for monitoring the responses of the treatment center population to particular drug formulations.

According to Zacharoff, the findings show that NAVIPPRO data can be useful for measuring, in "real time," the relative rate of abuse of a particular drug in a vulnerable population, and in a specific geographic area of the country. "These data can help detect early signals of an emerging trend of abuse, which in turn allows for targeted prevention and intervention efforts, and for gauging the impact of those initiatives," he says.

To address the need for prevention and intervention, Inflexxion has incorporated into NAVIPPRO its award-winning, empirically validated educational programs. These programs include PainEDU.org, a comprehensive pain education website for health care professionals with nearly 20,000 subscribed clinicians of varying disciplines. As part of its educational offerings, PainEDU provides clinicians with access to clinically tested practice tools, such as the Screener and Opioid Assessment for Patients with Pain (SOAPP®).

Developed by Inflexxion, SOAPP is a brief, pen-and-paper self-report tool that enables health care providers to assess a patient's risk of addiction before initiating opioid therapy. It can be used in concert with the Current Opioid Misuse Measure (COMM)®, a complementary tool for identifying whether a patient, throughout the course of long-term opioid therapy, may be exhibiting aberrant behaviors associated with abuse of opioid medications.

The utility of SOAPP and COMM were recently highlighted in new guidelines by the American Pain Society and the American Academy of Pain Medicine on the use of opioid medications to treat chronic non-cancer pain. The guidelines, published in the February 2009 issue of The Journal of Pain (Volume 10, Number 2), recommend that clinicians routinely conduct a complete benefit-to-harm evaluation before starting opioid therapy, and do periodic follow-up screenings of patients who may be at risk for abuse or addiction.

"In the past, drug sponsors and consultants worked individually on programs designed to minimize risk in a hit-or-miss fashion, with very little modification of the initiatives based on outcomes. I believe that the FDA hopes that this new REMS development process will provide an opportunity for these groups to come together, working more closely to ensure that patients are treated appropriately, based on collected data, with the best medications available, and the highest level of safety and vigilance," says Zacharoff. "We at Inflexxion are committed to assisting all stakeholders - including the manufacturers, the FDA, and health care providers - in successfully navigating these issues and together improving the risk-benefit balance of opioid medications."

To learn more about NAVIPPRO, visit the website (www.navippro.com).

About Inflexxion, Inc.

Founded in 1989, Inflexxion creates innovative, award-winning behavioral health solutions for prevention, education, and disease management. Our grant-funded, clinically tested programs address substance abuse and addiction, chronic pain management, and other health and wellness issues. Our pharmaceutical risk management division provides Risk Evaluation and Mitigation Strategy (REMS) assistance to companies that research, manufacture, and market opioid pain medications and other therapeutic agents with potential abuse problems. Key offerings include NAVIPPROTM, ASI-MV® Connect, PainEDU.org, painACTION.com, and SOAPP®. Inflexxion is based in Newton, MA.

# # #

Contact Information Amanda Hemm

Inflexxion, Inc.

http://www.NAVIPPRO.com

617-614-0436

CIRM Completes Briefing Visit to Stemedica Cell Technologies

CIRM Completes Briefing Visit to Stemedica Cell Technologies

Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

San Diego, Calif. (PRWEB) March 2, 2009 -- Leadership of the California Institute for Regenerative Medicine ("CIRM") completed a two part visit to Stemedica Cell Technologies, Inc. ("Stemedica") to tour its manufacturing facility, R&D lab and corporate headquarters.

"I was glad to have the opportunity to visit Stemedica and get to know more about its leadership, plans for the future and to see first hand the assets and potential they represent to the stem cell movement in California", said Dr. Alan Trounson, President of CIRM. "We want to have strong working relationships with all sectors of California's stem cell industry, including for-profit companies like Stemedica."

Prior to Dr. Trounson's visit, Dr. Marie Csete, CIRM's Chief Scientific Officer had the opportunity to visit Stemedica's manufacturing facility and R&D laboratory. "We're delighted to see Stemedica make the effort to secure a clinical grade manufacturing license from the State of California. We believe this capability will aid numerous organizations in California and around the world in their efforts to manufacture stem cell products for clinical application", said Dr. Csete.

"We were pleased to have Dr. Trounson and Dr. Marie Csete visit our facilities and receive a briefing from our leadership", said Dr. Maynard Howe, Stemedica's Vice Chairman & CEO. "We continue to play a pivotal role in the evolution of the stem cell industry in California and believe a supportive working relationship with CIRM is an essential part of this process.

Stuart Lipton, M.D., Ph.D., Scientific Director and Senior Vice President of the Del E. Webb Center for Neuroscience, Aging and Stem Cell Research at the Burnham Institute for Medical Research, San Diego, CA, joined Dr. Trounson during his visit to Stemedica's manufacturing facility. "I was impressed with the progress that Stemedica has made on the licensing process for clinical grade allogeneic stem cell manufacturing and am excited about expanding our research relationship with the Stemedica team. Having a manufacturing resource like this in California will be a great asset to our entire research community. I anticipate that many CIRM-funded stem cell research institutions will take advantage of Stemedica's manufacturing facility that will soon become FDB (Food & Drug Board) cGMP licensed."

Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer organized the visits for Dr. Trounson, Dr. Csete and Dr. Lipton. "We're delighted that these outstanding leaders within California's stem cell movement took the time to find out more about Stemedica and our plans to lead this industry from a manufacturing standpoint. We will continue to seek the wise counsel of CIRM in an effort to align our efforts with theirs. In addition, we are expanding our collaborative research efforts with the Burnham Institute for Medical Research and several other California stem cell research institutions", said Dr. Tankovich.

About Stemedica Technologies, Inc.:

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

About CIRM:

The California Institute for Regenerative Medicine (CIRM) was established in 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. To date, the CIRM governing board has approved 229 research and facility grants totaling more than $614 million, making CIRM the largest source of funding for human stem cell research in the world. For more information, please visit http://www.cirm.ca.gov (http://www.cirm.ca.gov/).

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

# # #

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

Pennsylvania Law Firm Joins Efforts to Help Those Injured by Oral Sodium Phosphate (OSP) Products

Pennsylvania Law Firm Joins Efforts to Help Those Injured by Oral Sodium Phosphate (OSP) Products

The Pennsylvania lawfirm of Marcus & Mack have announced that they joined forces with a national law firm to help those injured by Oral Sodium Phosphate (OSP) products. The FDA issued an alert about oral sodium phosphates and the report that they were causing acute phosphate nephropathy in patients. Many patients suffered severe kidney injuries. The attorneys are reviewing and accepting cases for people who used OSP products for bowel cleansing before colonoscopy.

Indiana, Pennsylvania (PRWEB) March 1, 2009 -- The law firm of Marcus & Mack in Indiana, Pennsylvania has joined forces with the Tate Law Group to help those who may have been injured by Oral Sodium Phosphate (OSP) (http://www.marcusandmack.com). This action is a result of the December 11th announcement by the FDA alerting that Oral Sodium Phosphate products used for bowel cleansing prior to colonoscopy or other procedures may cause acute phosphate nephropathy.

The FDA stated that they have become aware of reports of acute nephropathy, a type of acute injury, associated with the use of oral sodium phosphate products.

The FDA is now requiring the manufacturer of Visicol and OsmoPrep to add Boxed Warning to the labeling for these prescriptions.

On the same day as the FDA alert, Fleet Laboratories voluntarily recalled its over-the-counter Phospho-soda products. Fleet issued a statement that "the recall decision was made to address the FDA's determination that oral sodium phosphate solutions used for bowel preparation prior to medical procedures such as colonoscopy should be available by prescription, and consumers should not be using over the counter products for bowel cleansing."

Acute phosphate nephropathy, also known as nephrocalcinosis, is a very serious kidney injury associated with the deposits of calcium-phosphate crystals in the renal tubes that can require a patient to need dialysis or a kidney transplant. In the most severe cases, acute phosphate nephropathy can lead to acute renal failure and even death.

The attorneys at Marcus & Mack are accepting clients who have suffered a kidney injury that may be the result of the use of an oral sodium phosphate. For more information about the oral sodium phosphate products or the Fleet Laboratories products please visit our website at http://www.marcusandmack.com or feel free to call our toll free number at 866-527-2161.

###

Contact Information Cynthia Miklos

Marcus & Mack

http://www.marcusandmack.com

(866)527-2161

SinoFresh Healthcare Inc. Files SEC Form 15

SinoFresh Healthcare Inc. Files SEC Form 15

SinoFresh Healthcare Inc. ("the Company") (OTCBB: SFSH.OB) announced that the Company voluntarily filed a Form 15 with the Securities and Exchange Commission ("SEC") on February 18, 2009, thereby, voluntarily suspending its reporting obligations under the Securities Exchange Act of 1934.

Venice, FL (PRWEB) February 26, 2009 --SinoFresh Healthcare Inc. ("the Company") (OTCBB: SFSH.OB) announced that the Company voluntarily filed a Form 15 with the Securities and Exchange Commission ("SEC") on February 18, 2009, thereby, voluntarily suspending its reporting obligations under the Securities Exchange Act of 1934.

As a result of filing the Form 15, the Company will no longer be required to file annual and quarterly reports with the SEC. The Company took this action in order to focus its resources on further developing and marketing its unique antiseptic nasal and sinus care product.

The Company's common stock will continue to be eligible for public trading, only now it will occur through the Pink Sheets ( www.pinksheets.com ) quotations system instead of the OTC Bulletin Board. The change in trading venue is to become effective within 90 days of filing with the SEC; however, SinoFresh Healthcare Inc. will suspend all periodic report filing with the SEC, effective immediately.

"An overwhelming amount of resources have been expended over the past several years for auditing, filing and legal expenses in the desire to maintain an OTC Bulletin Board listing," stated Charles Fust, CEO of Sinofresh Healthcare Inc. "Focusing our limited resources on reducing our debt load and establishing strategic relationships to market our Sinofresh Nasal Spray product best serves the interests of our shareholders. The Company takes this step after carefully considering the advantages and disadvantages of continuing registration reporting. The costs and administrative burdens associated with being a public company have significantly increased, particularly in light of the Sarbanes-Oxley requirements make current on-going reporting financially infeasible.

The Company plans to provide timely quarterly and annual reports pertaining to its financial performance and other announcements on its website and through the Pink Sheets Disclosure and News Service.

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. is dedicated to research efforts and products designed to eliminate causal agents in the area of upper respiratory health and the potential positive impact upon the reduction of mold, fungus, viral and bacterial pathogens using patented, innovative preventative measures. The company's lead product, SinoFresh(TM) Nasal and Sinus Care is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants is available nationwide.

This press release contains forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "targets," "projects," "believes," "seeks," "estimates" and similar expressions are intended to identify such forward-looking statements. These statements are based on the current expectations or beliefs of Sinofresh Healthcare Inc. management. They are not guarantees of future performance and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, we undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts: Sinofresh Healthcare Inc. 941-484-2929

###

Contact Information Charles Fust

SinoFresh HealthCare, Inc.

http://www.sinofresh.com

941-488-6464

Hissey Kientz, LLP Announces Its Support For A New Bill That Would Protect The Rights Of Victim Of Asbestos Exposure Who Have Developed Malignant Mesothelioma

Hissey Kientz, LLP Announces Its Support For A New Bill That Would Protect The Rights Of Victim Of Asbestos Exposure Who Have Developed Malignant Mesothelioma

Hissey Kientz, LLP announces its support for a new bill that would protect the rights of victim of asbestos exposure who have developed malignant mesothelioma. “This is an important bill that would ensure that the legal rights of individuals in Texas who have developed mesothelioma after being exposed to asbestos are protected,” said attorney Robert Kientz.

February, 26, 2009, Austin, Texas (Vocus) February 27, 2009 -- The law firm of Hissey Kientz, LLP wishes to announce its support for a new bill that would make it easier for sufferers of malignant mesothelioma to prove that their injuries were caused by exposure to asbestos. The bill (Senate Bill No. 1123 and House Bill 1811) was filed jointly this week by congressmen from the Texas State Senate and House of Representatives.

“This is an important bill that would ensure that the legal rights of individuals in Texas who have developed mesothelioma after being exposed to asbestos are protected,” said attorney Robert Kientz of Hissey Kientz, LLP.

Mesothelioma (http://www.mesotheliomalawyershelp.com/about-mesothelioma/what-is-mesothelioma/) is a deadly form of cancer caused by exposure to asbestos that can attack the lining of the heart, chest or abdomen. Thousands of individuals in the United States are diagnosed with mesothelioma every year as a result of asbestos exposure that occurred in the workplace or from products containing asbestos.

Under current standards of causation enacted by the Texas State Supreme Court (Georgia-Pacific Corporation v. Fred and Betty Stephens), plaintiffs who bring mesothelioma claims must meet the same strict legal requirements that were established for cases involving asbestosis. If enacted by the Texas Senate and House of Representatives, the new bill would provide for a lower causation standard for mesothelioma lawsuits (http://www.mesotheliomalawyershelp.com/about-mesothelioma/mesothelioma-lawsuits/), making it easier for the victims of asbestos exposure to prove their case in court and recover fair compensation for their injuries.

“In an asbestosis case, the individual’s likelihood of developing the disease increases the more they were exposed to asbestos. But with mesothelioma, any level of exposure—no matter how small—is sufficient to cause the disease to develop,” said Kientz. “By forcing defendants in mesothelioma cases to meet the standard of causation for asbestosis, the Texas Supreme Court has set a benchmark for justice that is almost impossible these victims to meet.”

The new bill would remove the requirement for mesothelioma claimants “to prove, for any purpose, a quantitative dose, approximate quantitative dose or estimated quantitative dose of asbestos fibers to which the exposed person was exposed” in order to meet the standard of causation. Additionally, the law would protect defendants who were not involved in the manufacturing or sale of asbestos (http://www.mesotheliomalawyershelp.com/asbestos-info/what-is-asbestos/) but who may, under current law, be unfairly held responsible for injuries caused by asbestos products.

“By enacting this bill, the Texas legislature will help to bring the state’s laws relating to asbestos in accord with mainstream legal standards for mesothelioma cases and restore the intended function of these laws: to protect the legal rights of individuals who have suffered at the hands of the asbestos industry,” said Kientz.

About Hissey Kientz, LLP

Hissey Kientz, LLP (http://www.hkllp.com) is currently accepting cases involving individuals who may have contracted mesothelioma, asbestosis or lung cancer as a result of asbestos exposure, as well as those injured by the Ortho Evra patch, digoxin toxicity from Digitek, PPH caused by Fen-Phen, the Composix Kugel mesh hernia patch, renal failure caused by Trasylol, the Duragesic patch (fentanyl), gadolinium MRI contrast dyes or other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP (www.hkllp.com) or call toll-free at (866) 275-4454.

###

Contact Information Craig Whitney

Hissey Kientz, LLP

http://www.hkllp.com

512-320-9100

Healthy Living Network Announces Launch of New Detox Web Site

Healthy Living Network Announces Launch of New Detox Web Site

The Healthy Living Network, a division of Healthy Directions, LLC, is proud to announce the launch of searchbodydetox.com, a new informational Web site devoted to all aspects of whole body cleansing and detoxification.

Potomac, MD (PRWEB) February 25, 2009 -- The Healthy Living Network, a division of Healthy Directions, LLC, is proud to announce the launch of searchbodydetox.com (http://www.searchbodydetox.com), a new informational Web site devoted to all aspects of whole body cleansing and detoxification.

Visitors to searchbodydetox.com can expect to find original articles, blogs, studies, forums, encyclopedias, and more on a variety of topics and concerns, including environmental toxins, colon cleansing, liver detox, lymph and blood detox, skin detox, detox and weight loss, and nutrition and detox, as well as information on daily and quarterly detox programs. Searchbodydetox.com will also offer weekly eLetters so consumers can have continuous access to breaking news and up-to-date information.

According to Ed Hauck, President of Healthy Directions, "Each day, Americans are exposed to a staggering number of chemicals. Every time you eat, drink, clean your home, fertilize your lawn, or drive your car, this toxic load increases. In fact, more than 80,000 chemicals are registered with the Environmental Protection Agency, and more are added each year.

"At searchbodydetox.com, you'll have access to experts and authorities who can deliver effective answers to all of your detoxification (http://www.searchbodydetox.com) and body cleansing questions and concerns. Additionally, you'll find a plan of action to help reduce your risk of chemical exposure and toxic build up."

All information and advice found on searchbodydetox.com has been carefully screened and selected to provide the most current, ground-breaking, well-researched, and highly effective recommendations. While the majority of the experts and authorities on the site are doctors, the material on the Web site is intended to provide timely and accurate medical news and education, not personal medical advice, diagnosis, or treatment.

For more information about this exciting new resource for detox- and cleanse-related information, visit www.searchbodydetox.com (http://www.searchbodydetox.com).

About Healthy Directions, LLC

Healthy Directions, LLC, is the recognized leader in providing authoritative health and wellness solutions to consumers. Healthy Directions' subsidiary, Doctors' Preferred, LLC, is a leading vitamin and nutritional supplement business that develops and sells proprietary, branded nutritional supplements based upon the research of the Healthy Directions health experts, marketed primarily through direct mail. For more information on Healthy Directions, please visit www.healthydirections.com.

###

Contact Information Annette Payne

Healthy Directions, LLC

http://www.searchbodydetox.com

301-340-7788

Pharmacists Encourage Patients To Seek Their Guidance When Choosing OTC Medications

Pharmacists Encourage Patients To Seek Their Guidance When Choosing OTC Medications

Eighty-three percent of Patients Select OTC Products Recommended by Their Pharmacist

Washington, D.C. (Vocus) February 25, 2009 -- According to the most recent Pharmacy Today Over-the-Counter Product Survey conducted by the American Pharmacists Association (http://www.pharmacist.com/) (APhA), pharmacists believe that 83 percent of consumers purchase over-the-counter products that were recommended by their pharmacist. With more than 100,000 nonprescription medications on the market and more than 1,000 active ingredients, it's critical that patients consult their pharmacist to maximize the benefits from medications and minimize the potential for harmful drug interaction and/or side effects.

The survey, completed by nearly 1,000 APhA member and non-member pharmacists, also reveals that on average pharmacists counsel 31 patients per week about over the counter medications. Patients who seek their pharmacist's advice include patients suffering from an acute or chronic condition (92 percent), patients that are worried about using an OTC product with other prescription medications (84 percent), and patients worried about taking OTC products with a specific disease/condition (74 percent).

"Pharmacists are the only health professionals specifically trained in nonprescription medications," said John A. Gans, APhA's Chief Executive Officer. "Patients can take an active role in self care by reading medication labels, knowing the active ingredients in their medications, and asking their pharmacist questions."

One of APhA's goal in conducting the annual Pharmacy Today Over-the-Counter Product Survey is to educate consumers that pharmacists have the knowledge and training to help them select right OTC medications. As part of the survey, pharmacists are asked to tabulate the OTC products they recommend per week in 77 different product categories. The results of the survey are published as a supplement to the February issue of Pharmacy Today (http://www.pharmacytoday.org/index.htm). Click here to view the entire Pharmacy Today Over-the-Counter (http://www.pharmacytoday.org/index.htm) Supplement.

As the medication experts, pharmacists are trained in both prescription and over-the-counter medications and can provide patients with important information about how medications may interact with certain foods, other medicines or dietary supplements. Pharmacists are the most accessible health care providers and APhA encourages patients to actively seek their advice about the proper use of medications.

About the American Pharmacists Association (APhA)

The American Pharmacists Association (http://www.pharmacist.com/), founded in 1852 as the American Pharmaceutical Association, represents more than 62,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in advancing the profession. APhA, dedicated to helping all pharmacists improve medication use and advance patient care, is the first-established and largest association of pharmacists in the United States. APhA members provide care in all practice settings, including community pharmacies, health systems, long-term care facilities, managed care organizations, hospice settings, and the uniformed services.

###

Contact Information Erin Wendel

American Pharmacists Association

http://www.pharmacist.com/

202.429.7558

Clinical Guidelines for Treating Chronic Pain Highlight Opioid Addiction Risk Assessment

Clinical Guidelines for Treating Chronic Pain Highlight Opioid Addiction Risk Assessment

Expert panel finds that SOAPP® is likely to be helpful for risk assessment and stratification

Newton, MA (PRWEB) February 25, 2009 -- Inflexxion, Inc., a company that creates scientifically validated and cost-effective solutions for critical areas of health care, is pleased to announce that its Screener and Opioid Assessment for Patients with Pain (SOAPP) has been identified by an expert panel as likely to be helpful for assessing the risk of opioid addiction in patients with chronic non-cancer pain.

SOAPP is a brief paper-and-pencil self report tool that allows clinicians to assess a patient's risk of addiction before initiating opioid therapy.

The multi-disciplinary panel of experts, convened by the American Pain Society and the American Academy of Pain Medicine, conducted a comprehensive review of the evidence to develop a set of authoritative clinical guidelines on the use of opioid medications to treat chronic non-cancer pain. The guidelines, published in the February 2009 issue of The Journal of Pain (Volume 10, Number 2), recommend that clinicians routinely conduct a complete benefit-to-harm evaluation before starting opioid therapy, and do periodic follow-up screenings of patients who may be at risk for abuse or addiction.

"Proper patient selection is critical and requires a comprehensive benefit-to-harm evaluation that weighs the potential positive effects of opioids on pain and function against potential risks," write the authors. "Thorough risk assessment and stratification is appropriate in every case."

According to the authors, screening tools that assess the potential risks associated with continuous opioid therapy (COT) based on patient characteristics are likely to be helpful for risk stratification. The authors identify SOAPP Version 1 and the revised version, SOAPP-R, as among the tools that appear to have "good content, face, and construct validity."

In addition to SOAPP, the guidelines highlight the utility of Inflexxion's Current Opioid Misuse Measure (COMM)®, a complementary tool for identifying whether a patient, throughout the course of long-term opioid therapy, may be exhibiting aberrant behaviors associated with abuse of opioid medications.

"We at Inflexxion are very pleased to see both SOAPP and COMM included in these recommendations," says Kevin L. Zacharoff, M.D., Director of Medical Affairs at Inflexxion. "These guidelines underscore the importance of risk assessment and reassessment in this patient population. The inclusion of the SOAPP and COMM in these recommendations helps to validate Inflexxion's mission, which is to help to reduce health-related risks, enhance clinical outcomes, and positively influence quality of care."

The SOAPP and COMM tools are available for download at no cost through Inflexxion's PainEDU website (www.PainEDU.org), along with a clinician tutorial that includes video case examples.

SOAPP was developed by Inflexxion with support from the National Institutes of Health (NIH) and an unrestricted educational grant from Endo Pharmaceuticals.

About Inflexxion, Inc.

Founded in 1989, Inflexxion creates innovative behavioral health solutions for prevention, education, and disease management. Our clinically tested programs address substance abuse and addiction, chronic pain management, college health, and other health and wellness issues. Our pharmaceutical risk management division provides Risk Evaluation and Mitigation Strategy (REMS) assistance to companies that research, manufacture, and market opioid pain medications and other therapeutic agents with potential abuse problems. Key offerings include NAVIPPRO(TM), PainEDU.org, painACTION.com, and SOAPP®. Inflexxion is based in Newton, MA.

###

Contact Information Lara Romanowski

Inflexxion

http://www.painedu.org

617-614-0406

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials

Stemedica Cell Technologies, Inc. announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials.

San Diego, CA (PRWEB) February 25, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") announced today that it has filed with the Food and Drug Branch of the State of California's Department of Public Health for certification as a licensed manufacturer of adult stem cells for U.S.-based Phase I and Phase II Clinical Trials. Readiness for manufacture includes obtaining a California Drug Manufacturing License for the Stemedica facility in San Diego, California.

"Completion of this certification will allow us to manufacture stem cells under contract for clinical trials for Stemedica as well as for other companies and research centers in California and across the United States. This marks a significant milestone along the journey toward the future availability of stem cell treatment for patients who so urgently need it," said Dr. Maynard Howe, Vice Chairman and CEO at Stemedica.

To prepare for inspection, Stemedica fully reconstructed its facility according to FDA requirements, which had previously focused on research and development. Stemedica's manufacturing facility now includes a fully compliant manufacturing wing with entry-level gowning rooms, two ISO class 8 sterile gowning suites, an ISO Class 7 Manufacturing Clean Room, an ISO Class 7 Processing Clean Room, a Good Manufacturing Process compliant materials warehouse and a controlled-access Quality Control testing laboratory.

"As soon as Stemedica secures its license from the State of California's Department of Public Health, we plan on filing for one or more IND's (Investigative New Drug) for specific indications with the FDA using our proprietary technology. The final major step by the Food and Drug Branch within the Department of Public Health is an in-depth, in-person inspection by their personnel. We're particularly proud of the fact that we are ready for, and capable of, seeking licensing in California, which has exceptionally stringent standards," said Dr. Alex Kharazi, Vice President, Research & Manufacturing at Stemedica.

"Becoming a Licensed Manufacturer of clinical grade adult stem cells is a significant scientific and medical step forward for the Company," said Dr. Nikolai Tankovich, Stemedica's President and Chief Medical Officer. "Securing this status will allow us to become a primary CMO (Contract Manufacturing Organization) for other for-profit companies and the many research organizations interested in advancing stem cell research through clinical application. Additionally, achieving this regulatory status within the manufacturing world will provide Stemedica with the foundation to advance its own Phase I and Phase II Clinical Studies once approved by the FDA."

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan -- dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910

New survey: Flu Shot Still not Catching on, Especially at Retail Clinics

New survey: Flu Shot Still not Catching on, Especially at Retail Clinics

A new survey from global market research firm Synovate shows that less than half of Americans (42%) received the flu vaccine during the past six months. Of those, only 10% received it at a pharmacy and just 4% received it at a retail clinic.

Chicago, IL (PRWEB) February 24, 2009 -- According to a new survey by leading market research firm Synovate, less than half of Americans (42%) received the flu vaccine during the past six months. Of those, only 10% received it at a pharmacy and just 4% received it at a retail clinic.

Although there is a much higher rate of flu vaccination among older Americans 65+ (80%), especially compared to those in younger age groups, this is still lower than the federal government's target of 90% flu immunization for the elderly.

"While most older Americans have accepted the importance of the flu shot, adoption among those who are younger is still quite low," said Terri Crudup, Vice President for Synovate's Healthcare practice. "This is likely because the messages they've heard have focused on the elderly and those working with people who are ill - such as hospital workers - needing it more than the general population."

Among respondents with at least one dependent in their household, less than half (42%) report that their dependent(s) received the flu vaccine in the past six months, and the majority of them (74%) obtained the flu vaccine from their pediatrician's office.

Of those who had obtained the flu vaccine in the past six months, the majority report having received the vaccine either from their doctor's office (43%) or from their employer (23%). Pharmacies and retail clinics in large stores were less popular venues, especially among those aged 18 to 44, suggesting either low patient awareness or low acceptance of such venues for healthcare access.

"Even though retail clinics are actively advertising their ability to give the flu vaccine, it's clear that people are not often using them for that purpose," said Crudup. "This may be because they don't trust retail clinics, they think that their health insurance will only cover the flu vaccine if it's obtained at a doctor's office and / or that they receive their flu shot when they're visiting the doctor for another reason."

Not surprisingly, people in the lowest annual household income bracket (under $25K) are significantly less likely to obtain the flu vaccine compared to those in higher income brackets.

The survey was conducted by Synovate Healthcare (www.synovate.com/healthcare) via Synovate's Omnibus service (www.synovate.com/whatwedo/omnibus-research) with a nationally representative sample of 879 heads of household ages 18+ during January 2009.

About Synovate

Synovate, the market research arm of Aegis Group plc, generates consumer insights that drive competitive marketing solutions. The network provides clients with cohesive global support and a comprehensive suite of research solutions. Synovate employs over 6,000 staff across 62 countries.

For more information on Synovate visit www.synovate.com.

###

Contact Information Jennifer Chhatlani

Synovate

http://www.synovate.com

1-312-526-4359

Argo Translation Adds New Resources for Conducting Global Business to ArgoTrans.com

Argo Translation Adds New Resources for Conducting Global Business to ArgoTrans.com

Argo Translation, provider of efficient, accurate translation and localization services (http://www.argotrans.com) focused on quality and clarity for a wide range of companies across North America, announced today it has initiated a new program of adding global business reference material to its website as part of its ongoing commitment to new and existing clients.

Chicago, IL (Vocus) February 24, 2009 -- Businesses of all sizes continue to strive for new revenue opportunities through the expansion of global markets for their products and services. However, “Conducting business in legally and culturally sensitive ways in offshore markets has never been more challenging,” said Peter Argondizzo, president of Argo Translation.

In order to help its current and future clients step up to these new demands, Argo has committed to expanding the reference materials and recommendations it makes through its website at http://www.argotrans.com/resources.php.

The resources offered in this section will include a list of informative books that cover many aspects of doing business in global markets. There will also be a section devoted to technology issues and tips for preparing documentation and marketing materials for a global audience.

About ARGO Translation

Having successfully executed projects requiring simultaneous translations in 46 different languages, ARGO Translation provides specialized and professional translation services for a multitude of domains ranging from legal and technical to marketing and financial and everything in between. Argo provides efficient, accurate translation and localization services focused on quality and clarity for a wide range of companies across North America.

###

Contact Information Katie Porter

Argo Translation

http://www.argotrans.com

+1.847. 901.4070

Worldwide Laser is Pleased to Announce Additional Laser Applications which are Environmental Friendly & Green

Worldwide Laser is Pleased to Announce Additional Laser Applications which are Environmental Friendly & Green

Worldwide Laser is committed to helping protect our environment by providing eco friendly laser systems including Co2, Yag, Fiber, and UV that will eliminate the need for paper labels, ink solvents and chemicals from industrial production resulting in a safer, cleaner, more environmentally and earth friendly manufacturing process while providing maximum product identification and consumer protection.

Gilbert, AZ (PRWEB) February 23, 2009 -- Worldwide Laser is committed to helping protect our environment by providing eco friendly laser systems including Co2, Yag, Fiber, and UV that will eliminate the need for paper labels, ink solvents and chemicals from industrial production resulting in a safer, cleaner, more environmentally and earth friendly manufacturing process while providing maximum product identification and consumer protection.

Please take a look below at some of our recent environmentally friendly laser applications. Pictures are attached to the right and correspond to the descriptions below:

Laser Marking on Glass bottle in

beverage industry replaces paper label

Laser Marking bottles eliminates paper

labels in cosmetic and beverage products

Laser Marking glass eliminates paper label

Worldwide Laser provides earth friendly laser systems that will enhance product identification for it's customers allowing increased company recognition for end users. No chemical, no paper, and significantly reduced natural resource use in industry means eco friendly Laser Systems from Worldwide Laser. Contact us at 480.892.8566 option 5 or e-mail info@wlsc.com or visit www.wlsc.com for additional information.

More Pictures attached to the right.

Laser bar code Laser printing Laser date code & Laser printed date

replaces pad print replaces ink printer replaces ink printer

    

The positive environmental impact of laser systems from Worldwide Laser is especially visible in industrial applications where ink and adhesive paper labels are traditionally used. When the process of paper labels and the inks associated with paper labels is eliminated the positive environmental impact is significant, less paper production and less pollution associated with paper production, less ink used to print the labels, less glues and solvents used to apply the labels. Laser systems from Worldwide Laser provide all these benefits plus Co2 lasers, YAG, Fiber lasers, and UV laser systems from Worldwide Laser provide for eye appealing, easily readable product and company identification. In addition to the significant positive environmental impact of the laser systems, Worldwide Laser customers save money through the elimination of expenses related to the purchase of inks, solvents, glues and paper labels, also laser systems require no consumables or additives to operate and are maintenance free for up to five years.

Elimination of product contamination and creating an eco friendly manufacturing process which protects the environment and employees are areas and applications where laser systems from the Worldwide Laser family of eco friendly Co2, YAG, Fiber, & UV lasers provide important environmental protection and allow industry to produce products and consumer goods in an earth friendly environmentally sensitive manner. Using Worldwide Laser eco friendly laser systems eliminate the need for inks, chemicals, and solvents all of which are harmful to the environment and also contaminate the pharmaceutical, medical devise, and food product industries.

Laser Systems from Worldwide Laser including Co2, YAG, Fiber, and UV all have the ability to meet industrial production requirements, protect your products and customers with proper product identification and do so in an environmentally friendly and responsible manner. Eco friendly laser systems from Worldwide Laser will also help eliminate product contamination caused by ink, chemicals, and solvents. Product contamination is an important consideration in all industries for protection of consumers and employees and especially important in food, beverage, pharmaceutical and medical devise industries. Give us a call at 480.892.8566 option 5 or e-mail info@wlsc.com to discuss how our eco friendly laser systems can be used in your industry and at your facility.

Co2, YAG, Fiber, and UV laser systems from Worldwide Laser replace ink, chemical, & electro chemical etch marking methods resulting in a safer, cleaner, more environmentally and earth friendly manufacturing process while providing maximum product identification and consumer protection.

About Worldwide Laser

Worldwide Laser headquartered in Gilbert, Arizona and founded in July of 1986 builds laser cutting, laser marking, and laser engraving systems; types of systems are Co2, YAG, Fiber, and UV (10600nm, 1064 -1067nm and 355nm wavelength)

Worldwide Laser is one of the only remaining manufacturers of T.E.A. mask Co2 (LP2000 series) lasers which can be driven either by spark gaps or thyratrons. In the mask T.E.A. Co2 laser business Worldwide Laser is one of the leading suppliers for new and refurbished parts, laser systems and beam delivery components for Lumonics Laser Mark Series Lasers. Co2 lasers from Worldwide Laser can either be sealed beam or T.E.A and range from 10 to 400 watts. Worldwide Laser also builds diode and lamp pumped YAG (LP9000 series) lasers along with Fiber lasers for various laser marking, laser cutting, and laser etching operations. Worldwide Laser provides YAG and Fiber laser systems that range from 6 watts to 600 watts.

Worldwide Laser offers Galvo based and fixed beam laser systems either as stand alone or with complete product handling designed and built by the laser system experts in the Worldwide Laser systems division info@wlsc.com or www.wlsc.com.

Newly added are the LP9000U series of UV lasers at the 355nm wavelength which are ideal for many aerospace, medical, medical devise, pharmaceutical and laser marking plastic applications. The LP9000U series of lasers are extremely eco friendly and can often be deployed directly in clean rooms. The LP9000 YAG, Fiber, or UV laser systems along with the Co2 LP8000 laser series can be utilized for high speed and high quality laser marking or laser cutting.

Worldwide Laser has installed systems and service operations in 12 countries on 3 continents in addition to North America.

Worldwide Laser offers custom laser controller software & laser consulting and Worldwide Laser provides two levels of windows-based laser controller software for all of our environmentally friendly Co2, YAG, Fiber, & UV laser systems. (Zap-IT and Pro-Lase)

For added information contact 480.892.8566 option 5, e-mail info@wlsc.com or visit our website www.wlsc.com.

Let the laser experts at Worldwide Laser design and install the correct laser marking solution for your products and help build an earth friendly and green manufacturing process at your plant.

At Worldwide Laser we know lasers. Contact us today at 480.892.8566 option 5 visit www.wlsc.com.

In the previous newsletter we highlighted AspenWare www.aspenware.ca which produces extremely earth friendly wooden cutlery. This process can replace and eliminate the use of plastic spoons, forks, and knives which never degrade in land fills.

Please visit www.aspenware.ca for more information on wooden cutlery. Co2 laser systems from Worldwide Laser help Aspenware to keep the manufacturing process environmentally and earth friendly as the laser eliminates all inks, chemicals, and solvents otherwise required for marking company logos and consumer information.

# # #

Contact Information RONALD ANDERSON

Worldwide Laser Service Corporation

http://www.wlsc.com

480 892-8566

Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance

Carestream Molecular Imaging Releases Western Blot Kits For Added Convenience, Better Performance

Carestream Molecular Imaging today released convenient, cost-effective kits for performing western blots -- a popular analytical technique used to detect proteins.

New Haven, CT (Vocus) February 23, 2009 -- Carestream Molecular Imaging, a division of Carestream Health, Inc., today released convenient, cost-effective kits for performing western blots (http://mistore.carestreamhealth.com) -- a popular analytical technique used to detect proteins. KODAK X-SIGHT Western Kits provide industry-leading components and step-by-step protocols designed to deliver peak performance from X-SIGHT Nanosphere Conjugates in western blots.

"The X-SIGHT Nanosphere Conjugates, when used with the components supplied in the Western Kit, outperformed our current western blot method," said Kevin McCarthy, Ph.D., Professor, Department of Pathology, LSU Health Sciences Center-Shreveport. "The whole process was faster, easier and the signal obtained was immediate, more stable and brighter -- with less background noise."

KODAK X-SIGHT Western Kits are built on X-SIGHT Nanospheres (http://mistore.carestreamhealth.com), which are available in four distinct wavelengths including three in the near-IR range. The kits are offered in several different wavelength combinations that include up to three X-SIGHT Nanosphere Conjugates, making them ideal for multiplex applications (http://mistore.carestreamhealth.com). Each kit is optimized for 10 blots and includes best-in-class membranes and buffers to achieve high signal-to-noise ratios. A separate Accessory Kit is also available for use with any of the X-SIGHT Nanosphere Conjugates or any other commercially available fluorescently-labeled secondary antibody conjugate (nanoparticle or dye).

The new kit delivers added productivity and can reduce costs when compared with purchasing each component separately or in larger quantities than may be necessary. Components suppliers include Fisher BioReagents (Fairlawn, NJ) part of Thermo Fisher Scientific and Millipore Corporation (Billerica, Mass.).

The kits are available worldwide. U.S. customers can place orders directly or through channel partners. For more information, go to http://mistore.carestreamhealth.com.

About Carestream Molecular Imaging

Carestream Molecular Imaging group, a division of Carestream Health, Inc., develops and markets high performance digital imaging systems, imaging agents, film and accessories under the KODAK brand for the life science research and drug discovery/development market segments. For more information, visit mi.carestreamhealth.com or call 1-877-747-4357, express code 7. Outside of the United States, call 1-203-786-5657.

About Carestream Health, Inc.

Carestream Health, Inc., is a leading provider of dental and medical imaging systems and healthcare IT solutions; molecular imaging systems for the life science research and drug discovery/development market segments; and x-ray film and digital x-ray products for the non-destructive testing market. Headquartered in Rochester, N.Y., and serving customers in more than 150 countries, Carestream Health is an independent company operating within the family of companies owned by Onex Corporation (TSX: OCX.TO) of Toronto, Canada. For more information about Carestream Health, contact your Carestream Health representative or visit www.carestreamhealth.com.

KODAK is a trademark of Kodak used under license.

X-SIGHT is a trademark of Carestream Health.

###

Contact Information Jim Barillo

Carestream Health, Inc.

http://mistore.carestreamhealth.com

585-627-6440

Robette Brooks

CCS PR

303-699-8861

Reprints Desk Named to "KMWorld 100 Companies that Matter in Knowledge Management" List

Reprints Desk Named to "KMWorld 100 Companies that Matter in Knowledge Management" List

Reprints Desk, Inc., the content workflow company, today announced that the company has been named as one of "KMWorld's 100 Companies that Matter in Knowledge Management" by KMWorld Magazine.

Los Angeles, Calif. (PRWEB) February 23, 2009 -- Reprints Desk, Inc., the content workflow company (http://www.reprintsdesk.com/main/home.aspx), today announced that the company has been named as one of "KMWorld's 100 Companies that Matter in Knowledge Management" by KMWorld Magazine.

KMWorld's annual list, now in its eighth year, is compiled by knowledge management (KM) practitioners, theorists, analysts, vendors, and customers. Companies that have previously been named to the list include Google, Apple, Oracle, SAP, and EMC.

"Each company embodies as part of its culture agile and limber execution of its mission, embracing a spirit of both adaptability and innovation," said Hugh McKellar, KMWorld editor in chief.

In 2008, Reprints Desk achieved a number of accomplishments:

• Ranked first overall and in each category within the Document Delivery (http://www.reprintsdesk.com/main/docdel_overview.aspx) Best Practices and Vendor Scorecard Report published by Outsell, Inc.

• Served more than 50% of the world's top-50 pharmaceutical companies

• Launched eCTD Article Service (http://www.reprintsdesk.com/main/news.aspx) for regulatory submissions

• Established an office in Germany to support European sales

• Became a document supplier on FIZ Karlsruhe's full-text broker service FIZ AutoDoc

• Signed an agreement with the Copyright Clearance Center to integrate rights management from Rightsphere into the document delivery workflow

Reprints Desk is headquartered in Los Angeles, California, and was founded in 2006 by document delivery pioneer Peter Derycz. The company provides software services that simplify how healthcare companies and other research-oriented enterprises procure, manage, and share peerreviewed journal articles and other copyright-protected content.

About KMWorld

The leading information provider serving the Knowledge, Document and Content Management systems market, KMWorld informs more than 50,000 subscribers about the components and processes - and subsequent success stories - that together offer solutions for improving business performance. KMWorld is a publishing unit of Information Today, Inc.

About Reprints Desk ®

Reprints Desk, Inc. (www.reprintsdesk.com), is a content technology and services company that simplifies how healthcare companies and other enterprises procure, manage and share scientific journal articles and other copyright-protected content. The company's workflow solutions and end user tools help customers effectively use peer-reviewed literature in product promotions, regulatory submissions, and research. A channel supplier for more than 100 scientific, technical, and medical (STM) publishers, Reprints Desk currently serves more than half of the world's Top-50 pharmaceutical companies and earned the #1 ranking in the 2008 Document Delivery Vendor Scorecard by Outsell, Inc. Reprints Desk is a Derycz Scientific, Inc. (OTC: DYSC.PK) company. For more information about Reprints Desk, contact Ian Palmer at +1 (707) 658-1931.

Public and Media Relations Contacts:

Ian Palmer, Head of Marketing

Reprints Desk, Inc. | +1 707.658.1931

ipalmer @ reprintsdesk.com

# # #

Contact Information Ian Palmer

Reprints Desk

http://www.reprintsdesk.com

707.658.1931

Medicare-PartD.com Provides Seniors with a Preview of their 2010 Medicare Part D Prescription Drug Plan Costs

Medicare-PartD.com Provides Seniors with a Preview of their 2010 Medicare Part D Prescription Drug Plan Costs

Seniors can expect a smaller increase in 2010 Medicare Part D prescription drug plan parameters as compared to the increases they saw in 2009. Most Medicare Part D plan parameters, such as the initial deductible or out-of-pocket expense, will increase by only 3.13% in 2010, as compared to the 7.54% increase in the same values in 2009. To help the Medicare community better understand the 2010 changes, Medicare-PartD.com (http://www.medicare-partd.com/2010) has released the 2010 PDP-Planner, a simple to use online tool that illustrates how prescription drug costs change throughout the year and through the different phases of prescription drug coverage.

Saint Augustine, FL (Vocus) February 22, 2009 -- Seniors and Medicare beneficiaries can plan on increases in 2010 Medicare Part D prescription drug plan coverage parameters, but the changes are not so extreme as in previous years. Based on the recently released information from the Centers for Medicare and Medicaid Services (CMS), Medicare Part D plan parameters such as initial deductible, initial coverage limit and out-of-pocket threshold limits will increase in 2010 by 3.13% as compared to the 7.54% increase in 2009. An online summary comparing the CMS Medicare Part D defined standard benefit parameters from 2006 through 2010 are available at Medicare-PartD.com/2010 (http://www.medicare-partd.com/2010). Several of the 2010 low-income subsidy or extra-help values are still tentative and will be finalized as additional information becomes available.

To help seniors and other Medicare beneficiaries better understand the 2010 changes in the Part D plan benefit parameters, Medicare-PartD.com released their online 2010 PDP-Planner (http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php) tool. PDP-Planner allows users to visualize how they could potentially move through their Medicare Part D plan from initial deductible (if applicable) into the initial coverage phase, through the coverage gap, and maybe even into the catastrophic coverage portion of their Medicare Part D coverage.

"Unfortunately, even with three years of experience, we are finding that many people are still having difficulty understanding the coverage provided by their current Part D plans," noted Dr. Susan Johnson, technical director of the Medicare-PartD.com website. "It is our hope that the 2010 PDP-Planner will help Medicare Part D beneficiaries visualize prescription spending during the various phases of next year’s Part D plan coverage. To help people get started, we have provided a few PDP-Planner examples (http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php?pgtype=ex1) for those unfamiliar with the phases of a Medicare Part D prescription drug plan."

Users of PDP-Planner can enter estimated retail prescription costs based on their current drug spending and, if desired, change Medicare Part D plan parameters values, such as the initial deductible, to get an idea of how they will move through the phases of their Part D plan. For instance, a Medicare beneficiary who chooses a 2010 Part D plan modeled after the CMS defined standard plan will notice the slight increase in the initial deductible limits. The 2010 initial annual deductible will increase to $305 from the current 2009 value of $295. Beneficiaries will enter the 2010 donut hole or coverage gap when the total retail cost of their prescription drug purchases reaches the initial coverage limit of $2,780, an $80 increase over the 2009 Initial Coverage Limit of $2,700. In addition, people who enroll into a standard benefit plan with high prescription drug costs can begin to prepare for increases in total out of pocket expense (or TrOOP) that they must personally spend before exiting the donut hole and entering the catastrophic coverage portion of their prescription drug plan. The out of pocket threshold will increase to $4,500 in 2010 from the current 2009 value of $4,350.

"Our PDP-Planner is designed to provide an estimate based on the CMS defined standard benefit and, although most private Medicare Part D plans offer a variation of deductibles and cost-sharing options, we find that this defined standard benefit acts as a good benchmark for upcoming Part D coverage," added Dr. Johnson.

PDP-Planner is available at no cost and users have the option to have a copy of their PDP-Planner results sent directly to them via eMail. The 2009 PDP-Planner can be found at PDP-Planner.com/2010 (http://www.pdp-planner.com/2010) and joins the other online tools, resources, the free monthly Medicare Part D Newsletter (http://www.medicare-partd.com/PartD-StayingInformedOn-Medicare-PartD.php), and tutorials designed to help Medicare beneficiaries, advocates, advisors, and insurance agents navigate the Medicare prescription drug program.

About the Website Medicare-PartD.com

Medicare-PartD.com is one of the largest private internet resources for Medicare Part D prescription drug information. The Medicare-PartD.com website is designed and operated by Q1Group LLC (Saint Augustine, FL).

# # #

Contact Information Lynnea Christner

Q1Group LLC

http://www.medicare-partd.com/2010

904-461-8994

Susan Johnson MS-MIS, MBA, PhD

Q1Group LLC

http://www.medicare-partd.com/PartD-PartDCoverageGapCalculator10Xphp.php?pgtype=ex1

904-461-8994

Separating Fact from Bioidentical Hype

Separating Fact from Bioidentical Hype

Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The word "bioidentical" is not an accurate medical description of this new, unregulated substance and it certainly is not exactly like the hormones the body produces otherwise there would not be a measurable and clinically evident toxic build-up in the body. In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005), Dr. Theresa Dale offers a medically proven natural alternative to invasive and dangerous hormone replacement therapies. Dale invented the world's only clinically proven, FDA registered, homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects.

(PRWEB) February 19, 2009 -- Hot from Menopausal Symptoms and Bothered by the Media Hype about Hormone Replacement? People are hearing about bioidentical hormone replacement along with more traditional types of prescribed hormone medication from the Oprah show and other media. Lets separate Fact from Fiction. The new buzz word "bioidentical" is deceptive. It's not an accurate medical description of this new, unregulated substance and it is not exactly like the body produces. Clearly there is a measurable and clinically evident toxic build-up in the body.

Bioidentical hormone replacement is not natural even though it originates from yam or soy; it has been compounded and thus a synthetic. That's right; health providers perform thousands of before and after saliva tests on patients and it is clear that there is a toxic build up of all hormone replacement including bioidentical HRT.

Women are wary of recent warnings linking hormone replacement therapy with an increased risk for heart disease, stroke and breast cancer, more and more women are turning to alternative and natural ways to balance their hormone levels. Studies have shown that using hormones such as Prempro, Othro-Prefest or Premphase and bioidentical HRT causes the body to shut down production of its own hormones creating a dependency. Hormone replacement therapy can also elevate existing hormone levels to toxically high amounts, which can tax the adrenal glands, burden the liver, kidneys, and circulatory and immune systems.

Yet, there is a superior way to get both clinically proven and evidence based relief without being exposed to the toxic effects of ALL of these drugs. Health providers throughout the US are using FDA registered NuFem & EndoPure Homeopathic Hormone Rejuvenation, developed by Theresa Dale, ND, CCN, NP.

In "Revitalize Your Hormones: Dr. Dale's 7 Steps to a Happier, Healthier, and Sexier You" (Wiley; May 2005; $15.95/Paper), Dr. Theresa Dale offers a medically proven alternative to invasive and dangerous hormone replacement therapies. With over 20 years of experience as a Naturopathic Doctor, Certified Clinical Nutritionist and researcher, Dr. Dale has helped women balance their hormone levels through safe, non-toxic program. The world's only clinically proven homeopathic hormone rejuvenation formulas used for restoring hormone balance without side effects. These formulas actually produce healthy hormone levels in women of various ages, and eliminate symptoms such as hot flashes, mood swings, low libido, low energy and irregular menses. The formulas are FDA approved and regulated and are prepared at an FDA registered pharmacy. The remedy goes through a lengthy preparation processes. For example, an herb or substance is diluted and prepared in a manner so that just a micro amount of the original substance is left in the final formula. This method of natural preparation enhances all the properties of the herb and amplifies its efficacy. Homeopathic medicine has been used for 200 years throughout the world, and is natural without toxic side effects. See The Wellness Center website for more education about Homeopathy.

The medical establishment's approach to balancing hormones fails to embrace the concept of the body as a natural living system that is capable of self-repair. Its regimens are based on the premise that people need to look outside our bodies for hormone help via one-size-fits-all drugs. The only hormones that are safe for the human body are the ones the body makes. By using a totally natural and homeopathic program, it is possible to restore emotional, physical and sexual health by following simple and safe individualized nutritional and exercise guidelines.

For more information, call Theresa Dale's office at 866 962 6484.

Theresa Dale, ND, CCN, NP

Founder, The Wellness Center For Research & Education, Inc.

Dean, California College of Natural Medicine

www.wellnesscenter.net

###

Contact Information Theresa Dale

The Wellness Center

http://www.wellnesscenter.net

866 962 6484

Dr. Theresa Dale, ND, CCN, NP

The Wellness Center

http://www.wellnesscenter.net

805 984 7200

Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine

Cambridge Healthtech Institute's 7th Annual Bio-IT World Conference & Expo Enabling Technology - Leveraging Data - Transforming Medicine

The annual Bio-IT World Conference & Expo will be held April 27-29, 2009 at the World Trade Center in Boston, MA. Since its debut in 2002, the Expo has established itself as the premier event showcasing the myriad applications of IT and informatics to biomedical research and the drug discovery enterprise. The Expo is the perfect place to share ideas and innovation through networking, education, and recognition.

Needham, MA (PRWEB) February 19, 2009 -- Networking

The Expo provides the opportunity to make connections and build alliances with peers, prospects, and thought leaders. The Expo attracts a highly influential audience consisting of senior level scientists, IT professionals and Executives from organizations across the life sciences industry including Pharmaceutical, Biotechnology, Health Systems, Academia, Government and National Laboratories. Over 1,500 delegates representing 23 countries gather to share information and discuss enabling technologies that are driving the drug discovery process.

Education

The Expo provides over 140 technology and scientific presentations. The program features six parallel tracks in the areas of: IT Infrastructure, Genomic Medicine, Predictive and in silico Science, Computational Chemistry, Clinical and Medical Informatics, and Health IT.

Keynote presentations will be featured by Chris Dagdigian, Founding Partner and Director of Technology, BioTeam, Inc.; Clifford Reid, Ph.D., Chief Executive Officer, Complete Genomics, Inc.; and Eric E. Schadt, Ph.D., Executive Scientific Director, Genetics, Rosetta Inpharmatics/Merck Research Labs.

A plenary panel discussion on the exciting field of "personal genomics" will be held. Bio-IT World magazine's Editor-in-Chief, Kevin Davies Ph.D., will moderate the discussion that will feature the most outstanding scientists, physicians and commentators in the field: Robert C. Green, M.D., M.P.H. (Boston University School of Medicine and Public Health), John Halamka, M.D., M.S. (Harvard Medical School), Clifford Reid, Ph.D. (Complete Genomics, Inc.), and Dietrich Stephan, Ph.D. (Navigenics, Inc.).

In addition to the program, pre-conference workshops, user group meetings and research poster presentations are offered.

Recognition

Attendees can view novel technologies and solutions from 75+ companies in the expansive exhibit hall. Additionally, Cambridge Healthtech Institute and Bio-IT World recognize and celebrate leaders in innovation through its "Best of Show Award", "Best Practices Award", and "Benjamin Franklin Award" Programs. The Expo is honored to provide a forum to showcase the industry's talent and imagination.

The Bio-IT World Conference & Expo is the pulse of the industry. Every year, the Event is organically produced. Contributions from the life sciences community, Bio-IT World Magazine, and trend insights help determine the themes and topics that the Event will cover from year to year. The mission of the Event always stays the same: applied learning. Through networking, education, and recognition, participants can expect to apply knowledge gained to enable technology, leverage data and transform medicine. Please visit www.bio-itworldexpo.com for more information.

About Bio-IT World

Bio-IT World (www.bio-itworld.com), the flagship publication of Cambridge Healthtech Institute (CHI), is the leading source of news on technology and strategic innovation in drug discovery, development and clinical trials. Bio-IT World's focus is increasingly one that explores the tools and results of "predictive biology" as the industry adapts to the new world of "personalized medicine." Bio-IT World has won 34 national and regional awards, more than any other magazine covering the life sciences industry. Bio-IT World, part of Cambridge Healthtech Media Group--a division of CHI--also produces a comprehensive, continually updated website, topic-specific briefings, white papers, webcasts, podcasts, conferences, and the Bio-IT World Best Practices Awards. Established in 2001, the magazine is based in Needham, Mass.

About Cambridge Healthtech Institute (CHI)

Founded in 1992, Cambridge Healthtech Institute (CHI) (www.chicorporate.com) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Events, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Marketing Services, and Cambridge Healthtech Media Group.

Contact: Kaushik Chaudhuri

Cambridge Healthtech Institute

(781) 972-5419

###

Contact Information Tracey Fielding

781-972-5429